Noah Allen
Cerebras Systems posted a stronger than expected debut quarterly report as a public company, but the numbers did little to reassure investors. Shares of the AI chipmaker fell roughly 15% on Wednesday to around $192, touching their lowest point since the stock began trading last month.
At a Glance
- Cerebras (CBRS) dropped about 15% Wednesday to approximately $192 per share.
- First quarter revenue came in at $193.4 million, around $10 million above analyst consensus.
- Adjusted net loss of $2.48 million was narrower than Wall Street had forecast.
- Gross margin guidance for the current quarter: 36% to 38%, down from 47% in Q1.
- Morgan Stanley lifted its price target to $273 from $250, calling the results solid.
A Strong Quarter That Still Spooked the Market
Cerebras beat estimates on both the top and bottom lines in its first earnings report since going public. Revenue of $193.4 million exceeded the analyst consensus compiled by Visible Alpha by roughly $10 million, and the adjusted loss of $2.48 million came in smaller than forecasters had expected. On paper, that is a clean beat.
The problem is what comes next. Cerebras guided for adjusted gross margins of 36% to 38% in the current quarter, a meaningful step down from the 47% it achieved in Q1. That compression is what appears to be driving the selloff, as investors worry about costs eating further into profitability at a company that is not yet consistently profitable.
Where the Stock Stands After a Rough Start
The Wednesday decline extends what has already been a turbulent stretch. Cerebras only began trading last month, and the stock has been volatile from the outset. Wednesday's drop put shares about 40% below their closing price on the first day of trading. They are, however, still holding roughly 4% above the IPO price of $185, which offers at least a technical floor for early investors.
The slide reflects a broader tension common to freshly listed technology companies: a debut quarter that clears the bar can still disappoint if guidance signals slowing momentum.
Morgan Stanley Stays Bullish
Not everyone is reading the quarter negatively. Morgan Stanley analysts told clients Wednesday that they remain constructive on the stock and raised their price target to $273 from $250. Their reasoning: demand for Cerebras chips remains strong, and nothing in the reported numbers was genuinely disappointing. The analysts also suggested the company may be setting conservative targets as it finds its footing through its first few quarters in public markets, a common practice for newly listed companies managing investor expectations.
A price target of $273 implies substantial upside from current levels if the thesis holds, though the market's reaction Wednesday shows how much skepticism still surrounds the margin outlook.
Frequently Asked Questions
Why did Cerebras stock drop after beating earnings estimates?
Investors appear focused on the company's gross margin guidance for the current quarter, which came in at 36% to 38%, well below the 47% Cerebras posted in Q1. A beat on revenue and loss figures can still trigger selling when forward guidance signals cost pressure.
How far is Cerebras stock from its IPO price?
After Wednesday's decline, CBRS sits roughly 4% above its IPO price of $185. The stock is, however, about 40% below where it closed on its first day of trading.
What did Morgan Stanley say about Cerebras after earnings?
Morgan Stanley raised its price target to $273 from $250, maintaining a bullish view and arguing that Cerebras may be offering conservative guidance as a newly public company rather than signaling genuine weakness.
What revenue did Cerebras report for Q1?
Cerebras reported first quarter revenue of $193.4 million, which was approximately $10 million above the analyst consensus estimate compiled by Visible Alpha.
What to Watch Going Forward
The core question for Cerebras now is whether the margin compression in the current quarter is temporary or structural. Strong chip demand, as Morgan Stanley notes, is a real tailwind. But a 47% gross margin shrinking to the high 30s in a single quarter is the kind of move that keeps institutional investors cautious on a stock still finding its trading range. The next quarterly report will carry significant weight.
